A Nature Biotechnology report described an engineered UGA suppressor tRNA gene designed to extend therapeutic reach for adeno‑associated virus (AAV) delivery across disease contexts. The suppressor tRNA approach enables readthrough of UGA stop codons, potentially allowing modular AAV payloads to rescue diverse loss‑of‑function mutations with a single delivery platform. Authors demonstrated in vivo functionality and argued the strategy could support disease‑agnostic payload design, reducing the need to craft unique constructs for each monogenic disorder. The paper outlines molecular engineering, payload compatibility, and early in vivo expression data, while noting immunogenicity and long‑term safety remain critical for translation. If validated clinically, the suppressor tRNA platform could streamline AAV therapeutic pipelines and change program prioritization across rare genetic disease portfolios.